Richard E. Gilbert

Richard E. Gilbert

Auto-generated profile, based on publicly available information

Richard E. Gilbert

Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
RGRichard E. Gilbert
Richard E. Gilbert
The current view of diabetic kidney disease, based on meticulously acquired ultrastructural morphometry and the utility of measuring plasma creatinine and urinary albumin, has been almost entirely focused on the glomerulus. While clearly of great importance, changes in the glomerulus are not the major determinant of renal prognosis in diabetes and may not be the primary event in the development of diabetic kidney disease either. Indeed, advances in biomarker discovery and a greater appreciation of tubulointerstitial histopathology and the role of tubular hypoxia in the pathogenesis of chronic kidney disease have given us pause to reconsider the current “glomerulocentric” paradigm and focus attention on the proximal tubule that by virtue of the high energy requirements and reliance on aerobic metabolism render it particularly susceptible to the derangements of the diabetic state. Such findings raise important issues for therapeutic advances specifically targeting the pathophysiological perturbations that develop in this part of the nephron.

1 May 2015 in The Lancet
Verified
Journal Article
Closed access
RGRichard E Gilbert
Richard E Gilbert
HKHenry Krum
Henry Krum

4 September 2007 in Proceedings of the National Academy of Sciences of the United States of America
Verified
Journal Article
Closed access
PDF file
AAAndrew Advani
Andrew Advani
DKDarren J. Kelly
Darren J. Kelly
SASuzanne L. Advani
Suzanne L. Advani
ACAlison J. Cox
Alison J. Cox
KTKerri Thai
Kerri Thai
RGRichard E. Gilbert
Richard E. Gilbert
Inhibiting the actions of VEGF is a new therapeutic paradigm in cancer management with antiangiogenic therapy also under intensive investigation in a range of nonmalignant diseases characterized by pathological angiogenesis. However, the effects of VEGF inhibition on organs that constitutively express it in adulthood, such as the kidney, are mostly unknown. Accordingly, we examined the effect of VEGF inhibition on renal structure and function under physiological conditions and in the setting of the common renal stressors: hypertension and activation of the renin–angiotensin system. When compared with normotensive Sprague–Dawley (SD) rats, glomerular VEGF mRNA was increased 2-fold in transgenic (mRen-2)27 rats that overexpress renin with spontaneously hypertensive rat (SHR) kidneys showing VEGF expression levels that were intermediate between them. Administration of either an orally active inhibitor of the type 2 VEGF receptor (VEGFR-2) tyrosine kinase or a VEGF neutralizing antibody to TGR(mRen-2)27 rats resulted in loss of glomerular endothelial cells and transformation to a malignant hypertensive phenotype with severe glomerulosclerosis. VEGFR-2 kinase inhibition treatment was well tolerated in SDs and SHRs; although even in these animals there was detectable endothelial cell loss and rise in albuminuria. Mild mesangial expansion was also noted in hypertensive SHR, but not in SD rats. These studies illustrate: ( i ) VEGF has a role in the maintenance of glomerular endothelial integrity under physiological circumstances, ( ii ) glomerular VEGF is increased in response to hypertension and activation of the renin–angiotensin system, and ( iii ) VEGF signaling plays a protective role in the setting of these renal stressors.

1 April 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
AAAndrew Advani
Andrew Advani
RGRichard E. Gilbert
Richard E. Gilbert
KTKerri Thai
Kerri Thai
RGRenae M. Gow
Renae M. Gow
RLRobyn G. Langham
Robyn G. Langham
DKDarren J. Kelly
Darren J. Kelly
Excessive reactive oxygen species play a key role in the pathogenesis of diabetic nephropathy, but to what extent these result from increased generation, impaired antioxidant systems, or both is incompletely understood. Here, we report the expression, localization, and activity of the antioxidant thioredoxin and its endogenous inhibitor thioredoxin interacting protein (TxnIP) in vivo and in vitro. In normal human and rat kidneys, expression of TxnIP mRNA and protein was most abundant in the glomeruli and distal nephron (distal convoluted tubule and collecting ducts). In contrast, thioredoxin mRNA and protein localized to the renal cortex, particularly within the proximal tubules and to a lesser extent in the distal nephron. Induction of diabetes in rats increased expression of TxnIP but not thioredoxin mRNA. Kidneys from patients with diabetic nephropathy had significantly higher levels of TxnIP than control kidneys, but thioredoxin expression did not differ. In vitro, high glucose increased TxnIP expression in mesangial, NRK (proximal tubule), and MDCK (distal tubule/collecting duct) cells, and decreased the expression of thioredoxin in mesangial and MDCK cells. Knockdown of TxnIP with small interference RNA suggested that TxnIP mediates the glucose-induced impairment of thioredoxin activity. Knockdown of TxnIP also abrogated both glucose-induced 3H-proline incorporation (a marker of collagen production) and oxidative stress. Taken together, these findings suggest that impaired thiol reductive capacity contributes to the generation of reactive oxygen species in diabetes in a site- and cell-specific manner.

3 May 2019 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
RGRichard E. Gilbert
Richard E. Gilbert
KTKevin E. Thorpe
Kevin E. Thorpe

1 November 2007 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
KCK.A. Connelly
K.A. Connelly
DKD.J. Kelly
D.J. Kelly
YZY. Zhang
Y. Zhang
DPD.L. Prior
D.L. Prior
JMJennifer Helen Martin
Jennifer Helen Martin
RGR.E. Gilbert
R.E. Gilbert
Objective Diabetic cardiomyopathy is an increasingly recognized cause of cardiac failure despite preserved left ventricular systolic function. Given